|
1
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001.PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barber TW, Duong CP, Leong T, Bressel M,
Drummond EG and Hicks RJ: 18F-FDG PET/CT has a high impact on
patient management and provides powerful prognostic stratification
in the primary staging of esophageal cancer: a prospective study
with mature survival data. J Nucl Med. 53:864–871. 2012. View Article : Google Scholar
|
|
4
|
Bar-Shalom R, Guralnik L, Tsalic M,
Leiderman M, Frenkel A, Gaitini D, Ben-Nun A, Keidar Z and Israel
O: The additional value of PET/CT over PET in FDG imaging of
oesophageal cancer. Eur J Nucl Med Mol Imaging. 32:918–924. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berrisford RG, Wong WL, Day D, Toy E,
Napier M, Mitchell K and Wajed S: The decision to operate: role of
integrated computed tomography positron emission tomography in
staging oesophageal and oesophagogastric junction cancer by the
multidisciplinary team. Eur J Cardiothorac Surg. 33:1112–1116.
2008. View Article : Google Scholar
|
|
6
|
Kato H, Kimura H, Nakajima M, Sakai M,
Sano A, Tanaka N, Inose T, Faried A, Saito K, Ieta K, Sohda M,
Fukai Y, Miyazaki T, Masuda N, Fukuchi M, Ojima H, Tsukada K,
Oriuchi N, Endo K and Kuwano H: The additional value of integrated
PET/CT over PET in initial lymph node staging of esophageal cancer.
Oncol Rep. 20:857–862. 2008.PubMed/NCBI
|
|
7
|
Noble F and Bailey D; SWCIS Upper
Gastrointestinal Tumour Panel. Tung K and Byrne JP: Impact of
integrated PET/CT in the staging of oesophageal cancer: a UK
population-based cohort study. Clin Radiol. 64:699–705. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Omloo JM, van Heijl M, Hoekstra OS, van
Berge Henegouwen MI, van Lanschot JJ and Sloof GW: FDG-PET
parameters as prognostic factor in esophageal cancer patients: a
review. Ann Surg Oncol. 18:3338–3352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salahudeen HM, Balan A, Naik K, Mirsadraee
S and Scarsbrook AF: Impact of the introduction of integrated
PET-CT into the preoperative staging pathway of patients with
potentially operable oesophageal carcinoma. Clin Radiol.
63:765–773. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T,
Chen S, Yang X, Yang G, Guo H and Yu J: Additional value of PET/CT
over PET in assessment of locoregional lymph nodes in thoracic
esophageal squamous cell cancer. J Nucl Med. 47:1255–1259.
2006.PubMed/NCBI
|
|
11
|
Cerfolio RJ, Bryant AS, Ohja B and
Bartolucci AA: The maximum standardized uptake values on positron
emission tomography of a non-small cell lung cancer predict stage,
recurrence, and survival. J Thorac Cardiovasc Surg. 130:151–159.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sasaki R, Komaki R, Macapinlac H, Erasmus
J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA,
Roth JA and Cox JD: [18F]fluorodeoxyglucose uptake by positron
emission tomography predicts outcome of non-small-cell lung cancer.
J Clin Oncol. 23:1136–1143. 2005.
|
|
13
|
Cerfolio RJ and Bryant AS: Maximum
standardized uptake values on positron emission tomography of
esophageal cancer predicts stage, tumor biology, and survival. Ann
Thorac Surg. 82:391–395. 2006. View Article : Google Scholar
|
|
14
|
Cheze-Le Rest C, Metges JP, Teyton P,
Jestin-Le Tallec V, Lozac’h P, Volant A and Visvikis D: Prognostic
value of initial fluorodeoxyglucose-PET in esophageal cancer: a
prospective study. Nucl Med Commun. 29:628–635. 2008.PubMed/NCBI
|
|
15
|
Sobin LH and Wittekind C: TMN
classification of malignant tumors. 6th edition. John Wiley &
Sons; New York: 2002
|
|
16
|
Schisterman EF, Perkins NJ, Liu A and
Bondell H: Optimal cut-point and its corresponding Youden Index to
discriminate individuals using pooled blood samples. Epidemiology.
16:73–81. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujita H: Present status of esophageal
cancer and its treatment in Japan. Ann Thorac Cardiovasc Surg.
10:135–139. 2004.PubMed/NCBI
|
|
18
|
Hatt M, Visvikis D, Albarghach NM, Tixier
F, Pradier O and Cheze-le Rest C: Prognostic value of 18F-FDG PET
image-based parameters in oesophageal cancer and impact of tumour
delineation methodology. Eur J Nucl Med Mol Imaging. 38:1191–1202.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Westreenen HL, Plukker JT, Cobben DC,
Verhoogt CJ, Groen H and Jager PL: Prognostic value of the
standardized uptake value in esophageal cancer. AJR Am J
Roentgenol. 185:436–440. 2005.PubMed/NCBI
|
|
20
|
Yasuda T, Higuchi I, Yano M, Miyata H,
Yamasaki M, Takiguchi S, Fujiwara Y, Hatazawa J and Doki Y: The
impact of 18F-fluorodeoxyglucose positron emission
tomography positive lymph nodes on postoperative recurrence and
survival in resectable thoracic esophageal squamous cell carcinoma.
Ann Surg Oncol. 19:652–660. 2012.
|
|
21
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Natsugoe S, Uchikado Y, Okumura H,
Matsumoto M, Setoyama T, Tamotsu K, Kita Y, Sakamoto A, Owaki T,
Ishigami S and Aikou T: Snail plays a key role in
E-cadherin-preserved esophageal squamous cell carcinoma. Oncol Rep.
17:517–523. 2007.PubMed/NCBI
|
|
25
|
Sasaki K, Natsugoe S, Ishigami S,
Matsumoto M, Okumura H, Setoyama T, Uchikado Y, Kita Y, Tamotsu K,
Sakamoto A, Owaki T and Aikou T: Significance of Twist expression
and its association with E-cadherin in esophageal squamous cell
carcinoma. J Exp Clin Cancer Res. 28:1582009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Usami Y, Satake S, Nakayama F, Matsumoto
M, Ohnuma K, Komori T, Semba S, Ito A and Yokozaki H:
Snail-associated epithelial-mesenchymal transition promotes
oesophageal squamous cell carcinoma motility and progression. J
Pathol. 215:330–339. 2008. View Article : Google Scholar
|
|
27
|
Li Y, Ma J, Guo Q, Duan F, Tang F, Zheng
P, Zhao Z and Lu G: Overexpression of MMP-2 and MMP-9 in esophageal
squamous cell carcinoma. Dis Esophagus. 22:664–667. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mori M, Mimori K, Sadanaga N, Inoue H,
Tanaka Y, Mafune K, Ueo H and Barnard GF: Prognostic impact of
tissue inhibitor of matrix metalloproteinase-1 in esophageal
carcinoma. Int J Cancer. 88:575–578. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li K, He W, Lin N, Wang X and Fan QX:
Downregulation of N-cadherin expression inhibits invasiveness,
arrests cell cycle and induces cell apoptosis in esophageal
squamous cell carcinoma. Cancer Invest. 28:479–486. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fernando RI, Castillo MD, Litzinger M,
Hamilton DH and Palena C: IL-8 signaling plays a critical role in
the epithelial-mesenchymal transition of human carcinoma cells.
Cancer Res. 71:5296–5306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kato H, Takita J, Miyazaki T, Nakajima M,
Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Kuwano
H, Oriuchi N and Endo K: Correlation of 18-F-fluorodeoxyglucose
(FDG) accumulation with glucose transporter (Glut-1) expression in
esophageal squamous cell carcinoma. Anticancer Res. 23:3263–3272.
2003.PubMed/NCBI
|
|
32
|
Lee SY, Jeon HM, Ju MK, Kim CH, Yoon G,
Han SI, Park HG and Kang HS: Wnt/Snail signaling regulates
cytochrome C oxidase and glucose metabolism. Cancer Res.
72:3607–3617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Langer R, Specht K, Becker K, Ewald P,
Bekesch M, Sarbia M, Busch R, Feith M, Stein HJ, Siewert JR and
Hofler H: Association of pretherapeutic expression of
chemotherapy-related genes with response to neoadjuvant
chemotherapy in Barrett carcinoma. Clin Cancer Res. 11:7462–7469.
2005. View Article : Google Scholar : PubMed/NCBI
|
